Cullinan Oncology, Inc. announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial. This is a first-in-human, multi-center, open label study designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CLN-617 alone and in combination with pembrolizumab, a programmed death receptor-1 (PD-1) targeted checkpoint inhibitor, in patients with advanced solid tumors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.1 USD | +4.04% | +48.76% | +175.76% |
Apr. 29 | Cullinan Therapeutics Appoints Mary Kay Fenton as CFO | MT |
Apr. 29 | Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+175.76% | 1.16B | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines